How were Pfenex's earnings last quarter?

Pfenex Inc. (NYSEAMERICAN:PFNX) posted its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.07. The biotechnology company had revenue of $0.68 million for the quarter, compared to analyst estimates of $3.75 million. Read the conference call transcript .

What other stocks do shareholders of Pfenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) , Viking Therapeutics (VKTX) , Verastem (VSTM) , SCYNEXIS (SCYX) , TG Therapeutics (TGTX) , TherapeuticsMD (TXMD) , Gilead Sciences (GILD) , Novavax (NVAX) and Ocular Therapeutix (OCUL) .

How do I buy shares of Pfenex?

Shares of PFNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:PFNX

Pfenex (PFNX) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free PFNX Stock Alerts

$12.75

0.00 (0.00%)

(As of 10/1/2020)

Compare

Today's Range: $12.75
▼
$12.75
50-Day Range: N/A
52-Week Range: $5.26
▼
$14.00

Volume: N/A
Average Volume: 503,865 shs
Market Capitalization: $437.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Pfenex alerts:

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About Pfenex Stock (NYSEAMERICAN:PFNX)

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

PFNX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PFNX Stock News Headlines

January 31, 2024 | morningstar.com

NKY Medical Holdings Ltd Class A 300109

September 25, 2022 | seekingalpha.com

Ligand Pharmaceuticals: Struggling Along (NASDAQ:LGND) - Seeking Alpha

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

August 15, 2022 | businesswire.com

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update - Business Wire

August 9, 2022 | businesswire.com

Ligand Reports Second Quarter 2022 Financial Results - Business Wire

August 8, 2022 | stockhouse.com

2022-08-08 | NDAQ:LGND | Press Release | Ligand Pharmaceuticals Incorporated - Stockhouse

May 17, 2022 | finance.yahoo.com

Osteoporosis Therapeutics Market to Top US$ 14 Bn Valuation by 2026: Fact.MR Analysis - Yahoo Finance

May 5, 2022 | streetinsider.com

Ligand Reports First Quarter 2022 Financial Results - StreetInsider.com

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

May 4, 2022 | marketscreener.com

Ligand Reports First Quarter 2022 Financial Results - Marketscreener.com

March 29, 2022 | seekingalpha.com

Ligand Pharmaceuticals: Moving Parts Keep Moving - Seeking Alpha

March 24, 2022 | prnewswire.com

Global Pharma, Biotech and Diagnostics Joint Venture Partnering Deal Terms and Agreements Analysis Report 2021 with Example Case Studies of Agila Specialties/Pfenex and Dance Biopharm/Harmony Asset - PR Newswire

February 17, 2022 | businesswire.com

Ligand Reports Fourth Quarter and Full Year 2021 Financial Results - Business Wire

February 15, 2022 | businesswire.com

Pipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors - Business Wire

January 14, 2022 | marketscreener.com

LIGAND PHARMACEUTICALS INC : Termination of a Material Definitive Agreement (form 8-K) - marketscreener.com

January 5, 2022 | businesswire.com

Dr. Hubert Chen Joins ADARx Pharmaceuticals as Chief Medical Officer - Business Wire

November 10, 2021 | nasdaq.com

Solid Nutrition Unit to Aid Archer Daniels (ADM) Amid Cost Woes - Nasdaq

November 10, 2021 | nasdaq.com

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - Nasdaq

November 10, 2021 | nasdaq.com

fuboTV Falls 7% Despite Solid Q3 Results - Nasdaq

November 9, 2021 | marketscreener.com

LIGAND PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com

November 9, 2021 | businesswire.com

Ligand Reports Third Quarter 2021 Financial Results - Business Wire

September 23, 2021 | benzinga.com

Global Joint Venture Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021 - B - Benzinga

September 7, 2021 | yahoo.com

Ophthalmology Biosimilars Market Report 2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast - Yahoo Finance

July 30, 2021 | fool.com

Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript - Motley Fool

July 29, 2021 | businesswire.com

Ligand Reports Second Quarter 2021 Financial Results - Business Wire

See More Headlines

Receive PFNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfenex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/07/2020
Today: 4/15/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:PFNX
Previous Symbol: NYSEMKT:PFNX
CUSIP: N/A
CIK: N/A
Web: www.pfenex.com
Phone: +1-858-3524400
Fax: N/A
Employees: 71
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 34,297,000
Free Float: N/A
Market Cap: $437.29 million
Optionable: Not Optionable
Beta: N/A

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Evert B. Schimmelpennink (Age 47)
CEO, Pres, Sec. & Director
Ms. Patricia Lady C.M.A. (Age 61)
CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer
Mr. Patrick K. Lucy (Age 51)
Chief Bus. Officer
Dr. Hubert C. Chen (Age 50)
Advisor
Ms. Susan A. Knudson (Age 55)
Chief Financial Officer

Key Competitors

View All Competitors

PFNX Stock Analysis - Frequently Asked Questions

How were Pfenex's earnings last quarter?: Pfenex Inc. (NYSEAMERICAN:PFNX) posted its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.07. The biotechnology company had revenue of $0.68 million for the quarter, compared to analyst estimates of $3.75 million.
Read the conference call transcript.
What other stocks do shareholders of Pfenex own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Verastem (VSTM), SCYNEXIS (SCYX), TG Therapeutics (TGTX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), Novavax (NVAX) and Ocular Therapeutix (OCUL).
How do I buy shares of Pfenex?: Shares of PFNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:PFNX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pfenex (PFNX) Stock Price, News & Analysis

About Pfenex Stock (NYSEAMERICAN:PFNX)

PFNX Stock Price History

PFNX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

PFNX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info